Core Insights - Genentech, a member of the Roche Group, announced positive results from the Phase III evERA Breast Cancer study [1] - The study demonstrated that giredestrant in combination with everolimus significantly reduced the risk of disease progression or death [1] Study Results - The combination therapy reduced progression-free survival (PFS) by 44% in the intention-to-treat (ITT) population [1] - In the ESR1-mutated population, the risk of disease progression or death was reduced by 62% compared to standard-of-care endocrine therapy plus everolimus [1]